Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for livedo reticularis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for livedo was identified; there are no randomized controlled trials. Most livedo cases are physiologic (cold-related, benign cutis marmorata) and require no therapy beyond warmth and reassurance. Secondary livedo reticularis (associated with antiphospholipid syndrome, systemic lupus erythematosus, vasculitis, polyarteritis nodosa, cholesterol emboli, thrombophilia, or drug exposure) requires identification and treatment of the underlying condition by rheumatology or appropriate specialty. Leech therapy is contraindicated in active inflammatory or thrombotic disease.
- Main risks
- Missed diagnosis of a serious underlying condition (APS, lupus, vasculitis, PAN) if leech therapy is pursued instead of full workup
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over affected limbs for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Worsening of underlying inflammatory or thrombotic disease
- Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
- Triggering an ulcer in livedo-affected skin (livedoid vasculopathy ulcers heal poorly)
- Who should not consider this
- Patients with secondary livedo from an untreated underlying condition
- Patients with antiphospholipid syndrome with thrombosis history
- Patients on anticoagulants for APS, thrombophilia, or recurrent thrombosis
- Patients with active vasculitis, polyarteritis nodosa, or systemic lupus
- Patients with critical limb ischemia or recent cholesterol embolism
- Patients who have not had a rheumatologic and hematologic workup
- Patients with livedoid vasculopathy (ulcerative subtype - bleeding and ulcer risk)
- Patients with active dermatitis or broken skin over the livedo-affected region
- What to ask your clinician
- Has the livedo been classified as primary (benign physiologic) or secondary?
- Have I been screened for antiphospholipid antibodies, ANA, complement, and a hypercoagulable workup?
- Are there other systemic symptoms (joint pain, fatigue, rashes, organ involvement) suggesting an autoimmune cause?
- Has a skin biopsy been considered if vasculitis or cholesterol emboli are possible?
- What is my management plan if a secondary cause is found?
- What evidence supports leech therapy for livedo specifically?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Is this primary (idiopathic) livedo, livedoid vasculopathy, or livedo racemosa?
- Have I addressed cold avoidance, smoking, and any vasoconstrictor medications?
- When to seek urgent care
- Sudden severe leg pain, coldness, pallor, or pulselessness (acute limb ischemia — call 911)
- New unilateral leg swelling, redness, and pain (possible DVT)
- New stroke-like symptoms (weakness, slurred speech, vision change) — could indicate APS
- Recurrent pregnancy loss (APS workup needed)
- Painful skin ulcers within livedo areas (livedoid vasculopathy or vasculitis)
- Fever, joint pain, kidney symptoms, or new rash (autoimmune flare)
- Hives, throat tightness, or breathing difficulty
- Bleeding from a bite site lasting more than 24 hours
What this does NOT mean
- This is not FDA-cleared for livedo reticularis.
- Anecdotal use does NOT establish efficacy or rule out underlying systemic disease.
- Mechanism rationale (rheologic effects) does NOT replace the workup of secondary causes.
- Leech therapy is NOT a substitute for rheumatology and hematology evaluation.
- Secondary livedo from APS, lupus, vasculitis, or thrombophilia requires treatment of the underlying disease, NOT complementary therapy.
- Livedoid vasculopathy (the ulcerative subtype) is a serious bleeding risk and is not a candidate.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- R23.1, I73.89
- Safety tier
- High
Evidence Summary
No clinical study or case report of leech therapy for livedo reticularis was identified in PubMed, Europe PMC, ClinicalTrials.gov, Crossref, the Baskova and Isakhanyan (2004) monograph or a Russian-language web search, so no effect size can be assessed; the only mention found was a lay Russian-language health web page listing hirudotherapy among physical treatments, which is not a clinical report. Use is investigational and the rationale is mechanistic only. The proposed mechanism is local rheologic improvement from absorbed hirudin and salivary fibrinolytic enzymes. Secondary livedo (associated with antiphospholipid syndrome, vasculitis, or polyarteritis nodosa) requires identification and treatment of the underlying condition, and leech therapy is contraindicated until the inflammatory process is controlled. Primary livedo (cold-related, idiopathic) may be considered for symptomatic intervention only on an exploratory basis. Current ASH position: exploratory use only.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Secondary livedo with untreated underlying condition
- Active antiphospholipid syndrome with thrombosis
- Antiphospholipid syndrome (secondary livedo racemosa)
- Active vasculitis (PAN, cryoglobulinemia)
- Cholesterol embolization syndrome
- Recent corticosteroid use systemic >3 weeks
Related ASH Compounds
Leech molecules and hirudin-derived drugs mentioned for this condition, each profiled in the ASH compound registry:
Related Conditions
Raynaud's Syndrome (Primary)
Investigational use for primary Raynaud's phenomenon; the only clinical report is three patients in a 2025 Azerbaijani case series, with no controlled trial.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; no study in this condition was identified, only small series in venous ulcer and varicose disease.
Insulin Injection Lipohypertrophy
Investigational use for insulin injection-related lipohypertrophy nodules; no clinical study of leech therapy for them was identified.
Androgenic Alopecia
Investigational use for androgenic alopecia; the only clinical report is a single-patient Ayurvedic case study, with no controlled trial.